Biodegradable Bioadherent Microcapsules for Orally Administered Sustained Release Vaccines
Annual rept. 29 Apr 1996-28 Apr 1997
LYNNTECH INC COLLEGE STATION TX
Pagination or Media Count:
This research focuses on the development of an orally administered microencapsulated vaccine against botulinum neurotoxin type A using the non-toxic C-fragment of the neurotoxin Bot-Ac. The research focuses on the production through recombinant techniques and the incorporation of a known bioadhesive, vitelline protein B vpb, into the microsphere preparations to enhance uptake of the microspheres by the M cells located in the Peyers patches. The results demonstrate that vpB can be produced at 170-350 mgL in a Pichia pastoris expression system. iso, microspheres that contain 10 vpB generate a higher serum IgG level than microspheres that do not contain - B when administered either orally or subcutaneously. Whether vpB is acting as a true bioadhesive is still under study through the use of Peyers patch uptake experiments. For comparison it was also determined that when 2.0 g of 10 mm microspheres containing 89.9 BSA 10.0 vpB 0.1 Bot-Ac were administered subcutaneously, detectable serum IgG level was generated at 17 weeks post-immunization.
- Medicine and Medical Research